Imaging and chemical biomarkers for assessing the effectiveness of therapy in the first European investigator-driven clinical trial investigating the benefits of hypothermia in ischaemic stroke patients

在第一个欧洲研究者驱动的临床试验中，用于评估治疗有效性的成像和化学生物标志物，该临床试验调查了低温对缺血性中风患者的益处

• 批准号: nhmrc : 1037863
• 负责人: Prof David Howells
• 金额: $ 69.92万
• 依托单位: Antarctic Climate and Ecosystems CRC, University of Tasmania
• 依托单位国家: 澳大利亚
• 项目类别: Targeted Calls
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/imaging-chemical-biomarkers-stroke-patients/111104
• 关键词: Imaging; chemical; biomarkers; assessing; effectiveness

Hypothermia, entering phase III trial in Europe, has the potential to slow brain injury after stroke. It will allow existing thrombolytic therapies which restore critical brain blood flow to be used in many more patients than currently possible. However, hypothermia will soak up valuable resources if non-selectively applied to the ~15 million patients who have a stroke each year. We aim to identify biomarkers to test which patients will benefit most and permit the best resource allocation.

低温疗法在欧洲已进入第三阶段试验，有可能减缓中风后的脑损伤。它将允许现有的溶栓治疗，恢复关键的脑血流量，用于更多的患者比目前可能的。然而，如果非选择性地应用于每年约1500万中风患者，低温将消耗宝贵的资源。我们的目标是确定生物标志物，以测试哪些患者将受益最大，并允许最佳的资源分配。